Lilly Loses Around $14B This Week: How to Play LLY Stock
The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.
ENDPOINTS NEWS9h
Ei­sai to ask Aus­tralia to re­con­sid­er re­jec­tion of Alzheimer's drug Leqem­bi
Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...
pharmaphorum14h
NICE backs first targeted therapy for ALK+ lung cancer
In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
pharmaphorum15h
Australia joins EU in turning down Alzheimer's drug Leqembi
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
Eisai will request reconsideration of initial decision for lecanemab in Australia
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...